WallStSmart

Abbott Laboratories (ABT)vsiRhythm Technologies Inc (IRTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 5813% more annual revenue ($46.59B vs $787.85M). ABT leads profitability with a 11.7% profit margin vs -3.5%. ABT earns a higher WallStSmart Score of 52/100 (C-).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

IRTC

Avoid

30

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$105.62

$32.27 premium

UndervaluedFair: $73.35Overvalued

Intrinsic value data unavailable for IRTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

IRTC1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.7%8/10

Revenue surging 25.7% year-over-year

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

IRTC4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
24.9x2/10

Trading at 24.9x book value

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

Free Cash FlowQuality
$-33.08M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : IRTC

The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 25.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : IRTC

The primary concerns for IRTC are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 4.52 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while IRTC is a growth play — different risk/reward profiles.

IRTC carries more volatility with a beta of 1.27 — expect wider price swings.

IRTC is growing revenue faster at 25.7% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (52/100 vs 30/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

iRhythm Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.

Want to dig deeper into these stocks?